Safety, Efficacy and Doxorubicin Pharmacokinetics During Cannabidiol/Cannabidiolic Acid Rich Hemp Oil Use in Dogs With Lymphoma Undergoing CHOP Chemotherapy
Journal of Veterinary Internal Medicine · 01.07.2025 · 39 (4)
DOI: 10.1111/jvim.70179 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, online erschienen am 01.07.2025. Verfasst von Amandine Lejeune und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical and Radiological Sciences, University of California, School of Veterinary Medicine, Davis, California, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Cannabidiol, Dog Diseases, Doxorubicin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The safety of oral cannabidiol (CBD) and cannabidiolic acid (CBDA)-rich hemp oil supplementation in dogs with cancer receiving chemotherapy has not been investigated.
Objectives
To evaluate the safety, tolerability, and influence on doxorubicin exposure over time of oral CBD/CBDA-rich hemp oil supplementation in dogs diagnosed with high grade lymphoma undergoing CHOP chemotherapy. Animals Client-owned dogs diagnosed with lymphoma.
Methods
Dogs were enrolled in this prospective, double-blinded, randomized, placebo-controlled clinical trial to receive either CBD/CBDA-rich hemp oil capsules or placebo during one cycle of CHOP chemotherapy. Primary outcomes evaluated included adverse events during chemotherapy, quality of life scores and doxorubicin area under the curve (AUC) over a 5-week period.
Results
Twenty-five dogs were enrolled, with 19 completing the trial. CBD/CBDA supplementation did not significantly affect doxorubicin AUC in the intervention group. The doxorubicin AUC was not different between groups at week 0 [placebo 390.8 nM/h (318.6–479.4); CBD/CBDA 403.4 nM/h (351.9–462.5)] but was different at week 5 [placebo 572.6 (448.3–731.2); CBD/CBDA 406.8 (3.23.2–551.8)]. CBD/CBDA supplementation was well-tolerated, and no serious adverse events were observed. No significant differences between groups were observed in hematological and biochemical variables. The mean (range) quality of life scores for placebo and CBD were 7.56 (0, 35), and 10.75 (0, 56), respectively, with no significant differences. Conclusion and Clinical Importance Short-term oral CBD/CBDA-rich hemp supplementation appeared safe and well-tolerated in dogs undergoing CHOP chemotherapy for lymphoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgical and Radiological Sciences, University of California, School of Veterinary Medicine, Davis, California, USA.
- Department of Small Animal Clinical Sciences, University of Florida, College of Veterinary Medicine, Gainesville, Florida, USA.
- Department of Population Medicine and Diagnostic Sciences, Cornell University College of Veterinary Medicine, Ithaca, New York, USA.
- Department of Clinical Sciences, Cornell University College of Veterinary Medicine, Ithaca, New York, USA.
ORCID-Profile: Amandine Lejeune, Sandra Bechtel, Rowan Milner
Zitieren
APA
Lejeune, A., Bechtel, S., Milner, R., Fagman, L., Leal Yepes, F. A., & Wakshlag, J. J. (2025). Safety, Efficacy and Doxorubicin Pharmacokinetics During Cannabidiol/Cannabidiolic Acid Rich Hemp Oil Use in Dogs With Lymphoma Undergoing CHOP Chemotherapy. Journal of Veterinary Internal Medicine, 39(4). https://doi.org/10.1111/jvim.70179
Vancouver
Lejeune A, Bechtel S, Milner R, Fagman L, Leal Yepes FA, Wakshlag JJ. Safety, Efficacy and Doxorubicin Pharmacokinetics During Cannabidiol/Cannabidiolic Acid Rich Hemp Oil Use in Dogs With Lymphoma Undergoing CHOP Chemotherapy. Journal of Veterinary Internal Medicine. 2025;39(4). doi:10.1111/jvim.70179
BibTeX
@article{Lejeune2025,
author = {Lejeune, Amandine and Bechtel, Sandra and Milner, Rowan and Fagman, Lana and Leal Yepes, Francisco A and Wakshlag, Joseph J},
title = {Safety, Efficacy and Doxorubicin Pharmacokinetics During Cannabidiol/Cannabidiolic Acid Rich Hemp Oil Use in Dogs With Lymphoma Undergoing CHOP Chemotherapy},
journal = {Journal of Veterinary Internal Medicine},
year = {2025},
volume = {39},
number = {4},
doi = {10.1111/jvim.70179}
}
EUVIMED